Along with the [[retroprogesterone]] derivative [[dydrogesterone]], quingestrone is described as a "true" progesterone derivative or [[progestogen]] due to its close similarity to natural progesterone.<ref name="Wachtel1969">{{cite book | url=https://books.google.com/books?id=AcRsAAAAMAAJ | title=Exfoliative cytology in gynaecological practice | publisher=Appleton-Century-Crofts | author=Erica G. Wachtel | year=1969 | page=134 | LCCN=77008744}}</ref> Similarly to progesterone, dydrogesterone, and [[hydroxyprogesterone caproate]], quingestrone is a pure progestogen and lacks any [[androgen]]ic effects.<ref name="BairdKerr1969">{{cite book | author1=Dugald Baird | url=https://books.google.com/books?id=jbwwAAAAIAAJ | title=Combined textbook of obstetrics and gynæcology for students and practitioners | publisher=E. & S. Livingstone | author2=John Martin Munro Kerr | year=1969 | LCCN=70360656}}</ref> As such, it poses no risk of androgenic [[side effect]]s or [[virilization|virilizing]] [[teratogen]]ic effects on female fetuses.<ref name="BairdKerr1969" /> Accordingly, the drug was studied in the clinical prevention of [[miscarriage]] during [[pregnancy]]; however, insufficient efficacy was observed at the dosage assessed (100&nbsp;mg/day orally).<ref name="BurtonWachtel1967" /><ref>{{cite book|title=Vitamins and Hormones|url=https://books.google.com/books?id=rhbTtjo7dM4C&pg=PA332|date=9 February 1973|publisher=Academic Press|isbn=978-0-08-086627-7|pages=332–}}</ref><ref name="Fraser1998">{{cite book|author=Ian S. Fraser|title=Estrogens and Progestogens in Clinical Practice|url=https://books.google.com/books?id=eO5qAAAAMAAJ|year=1998|publisher=Churchill Livingstone|isbn=978-0-443-04706-0}}</ref><ref name="GoldsteinBerrier1989">{{cite journal | first1=Peter | last1=Goldstein | title=A meta-analysis of randomized control trials of progestational agents in pregnancy | last2=Berrier | first2=Jayne | last3=Rosen | first3=Scott | last4=Sacks | first4=Henry S. | last5=Chalmers | first5=Thomas C. | journal=BJOG: An International Journal of Obstetrics and Gynaecology | year=1989 | volume=96 | issue=3 | pages=265–274 | issn=1470-0328 | doi=10.1111/j.1471-0528.1989.tb02385.x | pmid=2653414}}</ref> Quingestrone is said to influence the [[hypothalamic–pituitary–adrenal axis]] similarly to [[progesterone]] and [[medroxyprogesterone acetate]], producing [[adrenal suppression]] at sufficiently high doses, and this suggests that it possesses weak [[glucocorticoid]] activity similarly to progesterone.<ref name="Martini1966">{{cite book | url=https://books.google.com/books?id=mp3wAAAAMAAJ | title=Neuroendocrinology | publisher=Academic Press | author=Luciano Martini | year=1966 | page=331 | LCCN=66026256}}</ref><ref name="SteinetzBeach1965">{{cite journal|last1=Steinetz|first1=B.G.|last2=Beach|first2=V.L.|last3=DiPasquale|first3=G.|last4=Battista|first4=J.V.|title=Effects of different gestagenic steroid types on plasma-free corticosteroid levels in ACTH-treated rats|journal=Steroids|volume=5|issue=1|year=1965|pages=93–108|issn=0039-128X|doi=10.1016/0039-128X(65)90134-0}}</ref>

 
Quingestrone has been suggested to act as a [[prodrug]] of progesterone via slow [[hydrolysis]] in the body.<ref name="BurtonWachtel1967">{{cite journal | first1=Eunice R. | last1=Burton | title=A CLINICAL TRIAL AND CYTOLOGICAL ASSESSMENT OF ENOL LUTEOVIS IN THE TREATMENT OF THREATENED AND RECURRENT ABORTION | last2=Wachtel | first2=Erica G. | journal=BJOG: An International Journal of Obstetrics and Gynaecology | year=1967 | volume=74 | issue=4 | pages=533–536 | issn=1470-0328 | doi=10.1111/j.1471-0528.1967.tb03986.x | pmid=5340429}}</ref><ref name="CharmanPorter1996">{{cite journal|last1=Charman|first1=William N.|last2=Porter|first2=Christopher J.H.|title=Lipophilic prodrugs designed for intestinal lymphatic transport|journal=Advanced Drug Delivery Reviews|volume=19|issue=2|year=1996|pages=149–169|issn=0169-409X|doi=10.1016/0169-409X(95)00105-G}}</ref> Indeed, it produces similar [[metabolite]]s (e.g., [[pregnanediol]]s and [[allopregnanediol]]s) as progesterone,<ref name="BurtonWachtel1967" /><ref name="pmid18472981">{{cite journal | vauthors = Fatouros DG, Karpf DM, Nielsen FS, Mullertz A | title = Clinical studies with oral lipid based formulations of poorly soluble compounds | journal = Ther Clin Risk Manag | volume = 3 | issue = 4 | pages = 591–604 | year = 2007 | pmid = 18472981 | pmc = 2374933 | doi = | url = }}</ref> although with differing ratios,<ref>http://www.popline.org/node/474452</ref><ref name="Hawkins1974" /> and notably is the only progestin that is known to produce pregnanediol as a metabolite.<ref name="CurrentMedicineAndDrugs1962">{{cite book | url=https://books.google.com/books?id=auc1AQAAIAAJ | title=Current Medicine and Drugs | year=1962 | quote=Enol Luteovis (3 cyclo-pentyl enol ether of progesterone) is the only oral progestin producing pregnanediol as a metabolite. It is not very potent and probably carries very little risk of producing virilizing effects on a female foetus. Thus it is more closely related to progesterone than the other synthetic progestins. | ISSN=0590-4048}}</ref> Subsequent research has cast doubt on the notion that quingestrone is a prodrug of progesterone however, and indicates that it instead is directly [[metabolism|metabolized]] into pregnanediols without [[metabolic intermediate|intermediate]] conversion into progesterone.<ref name="MeliWolff1965">{{cite journal|last1=Meli|first1=A.|last2=Wolff|first2=A.|last3=Lucker|first3=W. E.|last4=Steinetz|first4=B. G.|title=The Biological Profile of Progesterone 3-Cyclopentyl Enol Ether as Compared with That of Progesterone|journal=Experimental Biology and Medicine|volume=118|issue=3|year=1965|pages=714–717|issn=1535-3702|doi=10.3181/00379727-118-29947}}</ref>
